Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of TrovaGene Inc (NASDAQ: TROV) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of TrovaGene Inc (NASDAQ: TROV) concerning whether a series of statements by TrovaGene Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 28, 2016, TrovaGene Inc disclosed that its Board of Directors had terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni and filed a complaint against them for breach of fiduciary duty. According to the complaint, CEO Antonius Schuh and CFO Stephen Zaniboni failed to present a lucrative corporate opportunity to Trovagene Inc and instead took that prospect for their own personal benefit.

Following this news, NASDAQ: TROV shares dropped during intraday trading on March 29, 2016.

Based in San Diego, CA, and founded in 1999 TrovaGene Inc focuses on the development and commercialization of proprietary technology for the detection and monitoring of circulating tumor DNA in both urine and blood.

If you purchased shares of TrovaGene Inc (NASDAQ: TROV) on or before March 28, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185